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A b s t r a c t  
In the present study, dry free-flowing proniosomes containing Cefuroxime axetil has been prepared 
with sorbitol. Span 40, 60 and 80 have been used in different molar ratios with cholesterol and 
stearylamine. Proniosomes are characterized by SEM, flowability, entrapment efficiency, release 
study and ex-vivo permeation study. Stability study of proniosomes has been determined at room-
temperature. The vesicle size is found to be less than 5µm. Decreased angle of repose indicates the 
coating of niosomes with sorbitol carrier. Entrapment efficiency of Span 60 is found to be maximum. 
Both proniosomes and niosomes indicate the similar controlled release profile. Permeation study of 
cefuroxime axetil, follows the order of Span 60 with bile salt > Span 60 only > Span 40. Upon 
ageing, proniosomes indicate no change in its physical property and the entrapment efficiency is 
found to be more than 90%, indicating no leakage or degradation of drug from proniosomes 
whereas niosomes indicate slight sedimentation and aggregation of particles. These factors indicate 
the commercial viability and easy scale up of proniosomes. 




New generation dosage form mainly comprises of colloidal drug 
carrier system. The carrier serves to protect the drug from 
premature degradation, inactivation and protects the host from 
unwanted immunological or pharmacological effects [1]. Colloidal 
drug delivery system consists of nanoparticles, microparticles, 
microspheres, microemulsion, magnetic microspheres, resealed 
erythrocytes, liposomes and niosomes etc.[2] Encapsulation of a 
drug in vesicular structures can be predicted to prolong the 
existence of the drug in systemic circulation and perhaps reduce 
the toxicity if selective uptake can be achieved. Vesicular systems 
are of considerable interest because they can be used as 
membrane models, in chemical reactivity or in drug delivery and 
targeting [3].Liposomes are simple microscopic vesicles where an 
aqueous space is enclosed by lipid bilayers [4]. Because of their 
entrapping ability, liposomes are being considered as drug delivery 
structures or vesicles. But liposomes possess certain 
disadvantages associated with degradation by hydrolysis or 
oxidation and sedimentation, leaching of drugs, aggregation or 
fusion of liposomes during storage. Some problems associated 
with clinical applications of liposomes are the difficulties 
experienced in sterilization and large scale production. Moreover, it 
is difficult to obtain large quantities of sterile products with defined 
and reproducible properties that display adequate chemical and 
physical stability. The cost and purity of phospholipids is another 
limiting factor. They are suitable for parentral administration but 
oral administration is not possible because of the inability of 
liposomes to survive the action of bile salts and phospholipids. 
Tedious conditions dealt in handling liposomes under cryogenic 
atmosphere also prompted the use of non-ionic surfactant vesicles 
or niosomes as an alternative to liposomes. 
Since niosomes also suffer from the physical instability of aqueous 
niosomal dispersions like aggregation, fusion or leakage, the 
proniosomes have come into existence. They do not suffer from 
physical instabilities as well as their encapsulation efficiency is very 
high. They are capable of incorporating lipophilic, hydrophilic and 
amphiphilic drugs. The particle size distribution can be easily 
controlled. A vacuum or nitrogen atmosphere is not required for 
stability maintenance. All these characteristics point to the 
commercial viability of the proniosomes [3].  
Dry granular type of proniosomes involves coating of water soluble 
carrier such as sorbitol or maltodextrin with surfactant. The result of 
coating process is a dry formulation in which each water soluble 
particle is covered with thin film of surfactant. The proniosomes are 
reconstituted by addition of aqueous phase at a temperature 
greater than transition temperature and brief agitation. The 
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solubility (for ease of hydration), poor solubility in chloroform or in 
methanol (for ease of processing) and suitability for intravenous 
use. The sorbitol is reported to have offered the best compromise 
of desirable characteristics and has been selected for the present 
study. Though maltodextrin is also used as a water soluble carrier, 
it shows advantages only in preparation of the dry formulation but 
no significant change in the entrapment efficiency or drug release 
is reported through formulation of maltodextrin based proniosomes. 
Therefore sorbitol has been selected as the carrier for dry granular 
proniosomes. 
Among the cephalosporins, cefuroxime axetil belongs to second-
generation antibiotic, having the broad spectrum of activity and is 
active against β-lactamase producing strains. It is an ester prodrug 
of cefuroxime. Its activity depends upon in-vivo hydrolysis and 
release of cefuroxime [5]. Cefuroxime is rendered more lipophilic 
by esterification of the C4 carboxyl group of the molecule by the 
racemic 1-acetoxyethyl bromides, thus enhancing oral absorption. 
Cefuroxime axetil is an orally active drug though its absorption is 
incomplete. Its bioavailability is only 25%. It is the axetil form of 
cefuroxime that is absorbed but when it is hydrolysed to 
cefuroxime, its permeation is low [6]. So encapsulation of a drug in 
vesicular structures can be predicted to prolong the existence of 
the drug in systemic circulation and perhaps increase the 
bioavailability.  
Materials and Methods 
Materials 
Cefuroxime axetil was obtained from Torrent Pharmaceuticals, 
Ahmedabad, India as a gift sample. Span 40, 60, 80, Sorbitol, 
Cholesterol, Stearylamine, Sodium desoxycholate and dialysis bag 
were purchased from Sigma-Aldrich chemicals Private Limited, 
Bangalore, India. All other chemicals were of analytical grade.  
Methods 
Preparation of dry granular proniosomes 
1 gm of sorbitol was taken in a round bottom flask. It was attached 
to the rotary evaporator. Surfactant mixture was prepared in 
different ratios, along with cholesterol and stearylamine. 5 mg of 
the drug was introduced in the surfactant mixture. The surfactant 
solution was introduced into the round bottom flask on the rotary 
evaporator. During the spraying period, the rate of application was 
controlled so that the powder bed of the sorbitol did not become 
over wet. The rotating flask was then lowered into a water bath at 
65-700C. The flasks were rotated in the water bath under vacuum 
for 15-20 min or until sorbitol appeared to be dry. Another aliquot of 
surfactant solution was introduced. This process was repeated until 
all of the surfactant solution had been applied. After addition of final 
aliquot, evaporation was continued until the powder was 
completely dry. The material was further dried in desiccators under 
vacuum at room temperature overnight. The dry preparation was 
referred to as proniosomes [3].  
Proniosomes dry powder was then hydrated with 5 ml of phosphate 
buffer pH 7.4 at 800C and vortex mixing was performed for 2 min, 
to convert this into niosomes. 
Characterization of dry granular proniosomes 
The proniosomes prepared were characterized for particle size, 
surface morphology and polydispersity index by SEM and TEM, 
angle of repose for their flowability by funnel method, entrapment 
efficiency by dialysis, centrifugation and size exclusion 
chromatography, in-vitro drug release by dialysis and ex-vivo 
permeation study by everted sac-method. The stability study for 
proniosomes and niosomes were performed at room temperature.  
Morphological Characterization 
Morphological Studies (SEM) 
The surface morphology of dry granular proniosomes powder and 
hydrated proniosomes were examined by phase contrast 
microscopy (Manconi et. al) [7]. The sample of proniosomes and 
niosomal dispersion was taken in separate glass slide, covered 
with coverslip and then analyzed under optical microscope 
attached with camera (Nikon Eclipse E200) and photographs were 
recorded. The vesicular formulations were also observed under 
cross polarizer to study bilayer structures. 
Transmission electron microscopy (TEM) 
The morphology of derived niosomal dispersion was determined 
using transmission electron microscopy (TEM) (Philips- FEI 
Techai-12, Netherlands). A drop of niosome dispersion was 
cleaned with isotonic Phosphate buffer (IPB) pH 7.4 and applied to 
the carbon coated 300 mesh copper grid and left for 1min. Some 
niosomes were allowed to adhere to the carbon substrate. The 
remaining dispersion was removed by absorbing the drop with the 
corner of a piece of filter paper. After rinsing the grid twice (with 
deionised water for 3-5secs), a drop of 1 % uranyl acetate was 
applied for 10 sec. the remaining solution was removed by 
absorbing the liquid with the tip of a piece of filter paper and 
sample was air dried. The sample was examined in a TEM [5].  
Entrapment efficiency 
The entrapment efficiency of the niosomes was determined by 
dialysis, centrifugation and size-exclusion chromatography. 
Dialysis 
The unentrapped (free) cefuroxime axetil was removed from the 
niosomal dispersion by placing in a dialysis tube and exhaustively 
dialyzed against 300ml of phosphate buffer with 2 % methanol. The 
niosomes were lysed with 0.1 % v/v Triton X-100 and filtered with 
0.2 µm membrane filter. The drug content estimated by HPLC and 
Entrapment efficiency was calculated as: 
 
Entrapment efficiency= Total drug loaded-free drug    X 100 
                                           Total drug  
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Entrapment efficiency is used as a parameter in selecting the type 
of spans, surfactant mixture ratio and amount of drug encapsulated 
in proniosomes. 
 Centrifugation 
In this method, hydrated proniosomes were centrifugated at 14000 
rpm for 5 minutes and the supernatant were analyzed for free drug 
content. Entrapment efficiency was calculated using the above 
formula. 
Size-exclusion Chromatography 
In this method chromatographic column was packed using 
Sephadex 15. Then hydrated proniosomes were poured from the 
top. The clear and turbid eluate was collected separately. The clear 
portion was analyzed for free drug content, by HPLC method. 
Alternatively the Triton X could be added to turbid portions and the 
drug present inside the vesicle could be determined. 
Measurement of angle of repose 
The angle of repose of dry granular proniosomes powder was 
measured by the funnel method. The sorbitol powder and 
proniosomes were poured through a funnel that was fixed at a 
certain height. The powder flowed down from the funnel to form a 
cone on the surface, and the angle of repose was calculated by 
measuring the height of the cone (H) and radius of the base (R) by 
the formu 
                   Angle of repose, θ = tan-1 (H/R) 
In-vitro release rate  
In vitro release rate of proniosomes, derived niosome dispersion 
was carried out and the drug in 30% PEG was used as a control. 
Initially the treatment of dialysis tube was done by washing in 
running water for 3-4 hours to remove glycerin. The sulphur 
compounds were removed by treating it with 0.3 % w/v solution of 
sodium sulphide. Then it was washed in boiling water at 600C for 
0.5 hours, followed by acidification with 0.3 % v/v solution of 
sulphuric acid. Finally the membrane was rinsed with water and 
stored in phosphate buffer pH 7.4. Then 2ml of niosomal dispersion 
was placed inside the pretreated dialysis tube, tied at both the 
ends. It was then transferred to a beaker containing 20ml of 
phosphate buffer with 50% methanol. The assembly was stirred on 
a magnetic stirrer at 370C. 1ml samples were withdrawn at fixed 
intervals and replaced with equal volume of fresh media. The 
samples withdrawn were analyzed for drug by HPLC. 
Ex-vivo permeation study 
In-vitro absorption study of proniosomes formulation was done by 
everted sac method [7]. The small intestine of the rat was taken; it 
was washed with phosphate buffer pH 7.4, 6-7 times. Then the 
intestine was everted using the modified glass rod. It was then cut 
into 4-6cm pieces. One end of the intestine pieces was tied with 
thread, then 1ml of buffer was introduced in the intestine, and the 
other end was also tied. The intestine pouch was put in a test tube 
containing hydrated proniosomal dispersion. At different time 
intervals, the sample inside pouch was collected and analyzed for 
drug concentration. The pouch was again filled with fresh buffer 
medium, collected and analyzed.   
The samples collected were then extracted twice using hexane, 
then ether was added to vortexes for 2 min and ether layer was 
collected. This step was done twice. The samples collected were 
evaporated to dryness and then reconstituted with 1ml of mobile 
phase. It was then analyzed by using HPLC. 
Stability studies  
The proniosomes as well as niosomes of the same composition 
were kept at room-temperature as well as at 4OC. Upon two 
months of storage, the physical examination was done and also the 
entrapment efficiency was determined  
HPLC method  
HPLC method used for determination of drug content has been 
discussed by Zajac et al [8] with a flow rate of 1ml/min and RP C-
18 (Merck) column. 
Result and discussion 
Though niosomes function as sustained release systems showing 
reduced toxicity, eliminating problems of drug insolubility, irritancy 
and poor bioavailability, but they also show physical instability. 
During storage, the vesicles have natural tendency to undergo 
fusion and aggregation as well as chemical hydrolysis. To 
overcome these problems, proniosomes has been prepared by 
coating the surfactant mixture containing cefuroxime axetil over 
porous sorbitol to get free flowing particles, which on hydration 
transforms readily into opalescent vesicular dispersion or 
niosomes. Proniosomes are characterized for various parameters 
and contrasting features have been compared with conventional 
niosomes. The formulation composition of proniosomes is shown in 
Table 1.  The optimum composition has been chosen on the basis 
of entrapment efficiency. Upon hydration with water (preheated at 
700C) multilamellar vesicles (MLV) are formed with size ranging 
from 0.5- 5µm.The photomicrographs of dry granular proniosomes 
powder and niosomal dispersion under SEM are shown in Fig 1 & 
2 respectively. Scanning electron microscopy of uncoated sorbitol 
particles and dry proniosomes powder depicts a slight difference in 
the appearance of the surface of the two formulations. The sorbitol 
powder reveals some of the fine crystalline structures on the 
surface whereas the proniosomes powder appears to be smoother 
and to have fewer fine structures such as sharp edges. When the 
hydrated proniosomes are observed under SEM using cross 
polarizer, maltese cross was detected, indicating the formation 
bilayers as shown in Fig 3.  
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Upon hydration, it is converted to niosomes of average size 
between the range 200nm to 2.5µm. Transmission electron 
microphotograph has been shown in Fig 4. The vesicles seem to 
be like a spherical reservoir and devoid of any surface artifacts. 
The polydispersity index is very low indicating uniform dispersion.  
Entrapment efficiency is determined using dialysis, centrifugation 
and size exclusion chromatography. In all the cases, similar results 
have been found, so we restricted the use of dialysis method only. 
Maximum entrapment efficiency of 91.03±2 has been found in case 
of formulation 1b (i.e. span 60: cholesterol: stearylamine:: 67:30:3). 
Maximum entrapment in case of Span 40 and Span 60 could be 
attributed due to their structure, orientation and packing behavior 
[9], as both of them have same head group and different alkyl 
chain. Among the surfactants used, only Span 80 in formulation 1c 
has an unsaturated alkyl chain. The introduction of double bonds 
makes the chain bend. This means that adjacent molecule cannot 
be tight when they form the niosomes. This causes the membranes 
to be more permeable and therefore the yield of vesicle formation 
is appreciable which possibly explains the lowest entrapment 
efficiency. Span 60 has the longest saturated alkyl chain and 
shows the highest entrapment. Therefore the alkyl chain is the 
crucial factor for the permeability of long chain products. Moreover 
the Span 60 and span 40 are solid at room temperature and exhibit 
the higher phase transition temperature (Tc) that reflects the effect 
of phase transition temperature on the entrapment efficiency. 
Therefore Span 40 and Span 60 have been selected for further 
studies. As for vesicle size, increasing the hydrophobicity of the 
surfactant monomer leads to small vesicles. The order of 
increasing the vesicle diameter with various spans is as follows: 
Span 80 (formulation 1c) < Span 60 (formulation 1b) < Span 40 
(formulation 1a). 
This is because surface free energy decreases with the increasing 
hydrophobicity i.e. Span 80 < Span 60 < Span 40 [9].  
Maximum entrapment of drug (91.03±2) when Span 40: 
cholesterol: stearylamine were used in the ratio of 67:30.3 
(formulation 2d) and the formulation 2a showed minimum 
entrapment of 80.26±2 when ratio was 30:67:3. Above 70% 
concentration of nonionic surfactants in formulation led to a 
decrease in texture, shape and formation of vesicles. The 
concentration of stearylamine was kept constant. The amount of 
stearylamine was taken in accordance with the permissible 
concentration as reported in literature. The increase in entrapment 
efficiency in 2d formulation with 30 mM cholesterol could be 
explained by the fact that cholesterol was intercalated into the 
bilayers, thereby preventing the leakage of the drug through the 
bilayers[15] but a decline in the entrapment efficiency from 2c to 2a 
beyond a certain cholesterol level (55.0: 42.0: 3.0) could be 
attributed to the reason that when cholesterol is increased beyond 
the saturation limit, all the available spaces between the bilayers 
are filled up with the hydroxy moiety of cholesterol. It resulted in an 
increase in the rigidity of the vesicles [19]. Further addition of 
cholesterol would tend to destabilize the vesicle, leading to 
possible decrease of drug entrapment [31]. From Table 1, the 
entrapment efficiency remained high on increasing the amount of 
drug from 1 to 4mg which is attributed to higher log P value of the 
drug. The higher lipophilicity would facilitate interaction with 
surfactants and lipophilic ingredients [9]. But for experimental 
purpose 1gm of drug was taken for further study.  
 The flowability of proniosomes powder was compared with 
uncoated sorbitol powder (Table 2).  
The results revealed that the angle of repose of the proniosomes 
was smaller than that of sorbitol powder. As the angle of repose 
indicated the surface irregularity and roughness, the lower angle of 
repose of proniosomes confirmed that the surfactant coating of 
sorbitol powder had been achieved, resulting in the smoothening of 
surface. If the sorbitol powder was added to the proniosomes, the 
angle of repose was found increasingly approaching towards angle 
of repose of pure sorbitol powder. 
In vitro release rate of cefuroxime axetil from proniosomes was 
determined and compared with niosomes and drug in 30% 
Propylene glycol as shown in Fig 5 & 6. 
In conducting the experiment continuously almost 75% of drug was 
released within 5 hours in case of propylene glycol, while in case of 
niosomes and proniosomes, a clear sustained release profile was 
achieved releasing about 30% in 6 hours (Table 3). 
 In case of our formulations the drug release was evident even 
after 20 hours, 65% in case of proniosomes and 44% in case of 
niosomes, showing better performance of formulation.  
It has been documented that in dissolved condition and in the 
acidic environment of the stomach, the hydrolysis of the 
Cefuroxime axetil occurs, and it gets converted into the Cefuroxime 
and the absorption of the Cefuroxime as such is negligible. It is the 
axetil form of the Cefuroxime that is absorbed. So, the drug in 
Propylene glycol can overcome the problem of insolubility but not 
the permeability. But when the drug is entrapped in the vesicles, it 
can easily cross the membrane, protect the drug from acid 
environment and additional mechanism apart from phagocytic 
uptake which occurs thereby enhancing the drug absorption. 
In-vitro absorption (ex-vivo permeation) study using everted sac 
method has been shown in Fig 7 & 8.  
The formulation containing bile salt with Span 60 showed 
maximum absorption followed by formulation with Span 60 only 
then did various formulations of Span 40 come in (Table 4), 
thereby proving again that performance of drug depends on the 
entrapment efficiency.  
Upon storage of proniosomes and niosomes of same composition 
(1b) for two months, the visual examination revealed the 
sedimentation of niosomal dispersion whereas proniosomes 
appeared to be amorphous powder. When they were observed 
under SEM, marked aggregation was detected in case of niosomes 
and the mean particle size increased to 10 folds. But for 
proniosomes (just hydrated), a uniform dispersion was observed 
and aggregation was absent. When entrapment efficiency was 
determined for hydrated proniosomes (just prior to experiment) and 
niosomes that was already stored, a decrease in entrapment 
efficiency was observed, which was due to some leakage or drug 
degradation.   
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Table 1: Composition of various Proniosomal formulations  
· All the ratios are in milimole 
 
Table 2: Measurement of angle of repose of sorbitol powder and dry granular proniosomes 
S. NO. TYPE OF PREPARATION HEIGHT (H) ± 
S.D. (N=3) 
IN CM 
RADIUS (R) ± S.D. 
(N=3) 
IN CM 
TAN Θ = H/R ANGLE OF 
REPOSE 
Θ = TAN-1 (H/R) 
± S.D. (N=3) 
1 Sorbitol powder 1.8 3 0.6 30.964±2.1 
2 Proniosomes powder 1.5 3 0.5 26.565±2.1 
3 Proniosomes (with  double 
quantity of Sorbitol 
1.3 5 0.52 27.474±1.6 
 
     Table 3: The comparative release profile of conventional niosomes and dry granular proniosomes and Drug in 30% PG. 
 
Time (Hrs) % drug release 
proniosomes Niosome Drug in 30% PG 
0 0 0 0 
0.5 36.33±3.12 21.64±2.13 47.24±1.34 
1 25.10±2.24 35.44±2.13 70.45±2.31 
1.5 26.87±1.45 35.82±2.31 74.11±1.42 
2 27.28±3.24 37.95±3.24 77.04±2.31 
2.5 31.74±2.31 37.07±1.32 77.46±2.31 
3 31.03±2.56 35.37±2.13 71.73±1.34 
4 30.40±1.56 32.65±2.31 75.15±2.43 
4.5 31.96±3.24 31.56±2.31 - 
5 30.91±2.34 32.56±2.31 - 
5.5 29.68±1.56 32.77±3.23 - 
6 27.54±3.21 34.16±4.32 - 



















1a 5 1 67 - - 30 3 91.03±4 5 
1b 5 1 - 67 - 30 3 97.0±3 1-2 
1c 5 1 - - 67 30 3 nd 0.8-2 
2a 5 1 30 - - 67 3 80.26±2 - 
2b 5 1 47 - - 50 3 82.81±3 - 
2c 5 1 55 - - 42 3 83.74±4 - 
2d 5 1 67 - - 30 3 91.03±2 - 
3a 5 1 67 - - 30 3 91.03±2 - 
3b 5 2 67 - - 30 3 88.54±4 - 
3c 5 3 67 - - 30 3 89.46±3 - 
3d 5 4 67 - - 30 3 92.78±2 - 
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Table 4: In-vitro absorption study of various proniosomal formulations by everted sac method. 
Time Permeation Flux (mcg/cm2) 
(hours) 2a 2b 2c 2d 2e« 2f«« 
0 0 0 0 0 0 0 
0.5 1.86 2.4 2.17 2.04 2.18 3.03 
1 3.76 3.89 4.25 4.08 4.06 4.77 
1.5 6.36 5.17 6.43 5.45 8.38 7.27 
2 7.92 6.37 8.69 7 10.04 10.42 
  2e« formulation composition same as 2d but have Span 60 instead of Span 40. 
  2f«« formulation composition same as 2e with 10 mM bile salts. 
                      
   Figure 1: Surface morphology of dry granular                          Figure 2:  Hydrated proniosomes evident by SEM                  
                 proniosomes     
                     
   Figure 3: Hydrated proniosomes using cross polarizer        Figure 4:  TEM photomicrograph of Hydrated proniosomes 
 
Sambhakar et al. International Journal of Drug Delivery 4 (2) 236-245 [2012] 
 





    Figure 5: Release Profile of Proniosomes, Niosomes and drug in 30% PG in 6 hours 
 
 Figure 6: Release Profile of Proniosomes, Niosomes and drug in 30% PG in 20 hours 
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Figure 7: In-vitro absorption study of different formulations  
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An attempt has been made to prepare dry granular proniosomes 
which has been anticipated to provide improved stability as 
compared to conventional vesicular delivery systems in terms of 
aggregation, leakage etc. The proposed formulation based on 
present study is expected to have industrial scalability. This may 
also provide the high absorption inside the lumen and the same 
may be expected even in blood circulation. However, it will require 
a detailed study in terms of in-vivo behavior.  
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